Novartis Boosts HCV Portfolio With First-in-Class Debiopharm Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
Hepatitis C sector heats up as Novartis gains rights to Debiopharm's leading cyclophilin inhibitor
You may also be interested in...
Novartis’ Hepatitis C Drug Alisporivir Returns To Clinical Testing Minus Interferon
Phase II trial of alisporivir plus ribavirin began after FDA modified its partial clinical hold; previous regimen included peg-interferon.
Novartis And HGS Close The Door On Zalbin
Development of hepatitis C drug concluded after FDA "complete response" letter and disappointing monthly dosing data.
Novartis And HGS Close The Door On Zalbin
Development of hepatitis C drug concluded after FDA "complete response" letter and disappointing monthly dosing data.